Papers 2799
1 page of 280 pages (2,799 results)
#1Vijairam Selvaraj (Miriam Hospital)H-Index: 7
#1Selvaraj (Brown University)H-Index: 1
Last. Eleftherios Mylonakis (Brown University)H-Index: 84
view all 7 authors...
BackgroundTo date, only dexamethasone has been shown to reduce mortality in COVID-19 patients. Tocilizumab has been recently added to the treatment guidelines for hospitalized COVID-19 patients, but data remains conflicting. MethodsElectronic databases such as MEDLINE, EMBASE and Cochrane central were searched from March 1, 2020, until February 28th, 2021, for randomized controlled trials evaluating the efficacy of tocilizumab in hospitalized COVID-19 patients. The outcomes assessed were all-cau...
#1Alyn H. Morice (University of Hull)H-Index: 16
#1Thomas GlaabH-Index: 21
#2Armin Braun (Fraunhofer Society)H-Index: 63
Mouse models have become an indispensable tool in translational research of human airway disease and have provided much of our understanding of the pathogenesis of airway disease such as asthma. In these models the ability to assess pulmonary function and particularly airway responsiveness is critically important. Existing methods for testing pulmonary function in mice in vivo include noninvasive and invasive technologies. Noninvasive head-out body plethysmography is a well-established and widel...
#1César Fernández-de-las-Peñas (URJC: King Juan Carlos University)H-Index: 79
#2Carlos Guijarro (URJC: King Juan Carlos University)H-Index: 28
Last. Juan Torres-Macho (Complutense University of Madrid)H-Index: 5
view all 5 authors...
This multicenter study presents prevalence data and associated risk factors of post-COVID-19 cough one year after hospital discharge in COVID-19 survivors. Individuals recovered from COVID-19 at three public hospitals in Madrid (Spain) were scheduled for a telephonic interview. They were systematically asked about the presence of respiratory symptoms, e.g., fatigue, dyspnea, chest pain, and cough after hospital discharge. Clinical and hospitalization data were collected from hospital records. Ov...
#2Laura BergantiniH-Index: 12
Last. David BennettH-Index: 15
view all 11 authors...
BACKGROUND Galectins are proteins that bind β-galactosides such as N-acetyllactosamine present in N-linked and O-linked glycoproteins and that seem to be implicated in inflammatory and immune responses as well as fibrotic mechanisms. This preliminary study investigated serum galectins as clinical biomarkers in lung transplant patients with chronic lung allograft dysfunction (CLAD), phenotype bronchiolitis obliterans syndrome (BOS). MATERIALS AND METHODS Nineteen lung transplant patients [median ...
#1Andrew T. Arndt (Rush University Medical Center)H-Index: 3
#2Alessandro Brunelli (St James's University Hospital)H-Index: 57
Last. Christopher W. Seder (Rush University Medical Center)H-Index: 23
view all 12 authors...
Background Management of clinical stage IIIA-N2 (cIIIA-N2) non-small cell lung cancer (NSCLC) remains controversial. We evaluated treatment strategies and outcomes in cIIIA-N2 NSCLC patients who underwent pulmonary resection in The Society of Thoracic Surgeons General Thoracic Surgery Database (STS GTSD) and the European Society of Thoracic Surgeons (ESTS) Registry. Methods The STS GTSD and ESTS Registry were queried for patients who underwent pulmonary resection for cIIIA-N2 NSCLC between 2012 ...
#1Peter V. Dicpinigaitis (Albert Einstein College of Medicine)H-Index: 33
1 CitationsSource
#1Esther Rong (Montefiore Medical Center)
#2David A. Hirschl (Montefiore Medical Center)
Last. Arash Gohari (Montefiore Medical Center)H-Index: 1
view all 9 authors...
PURPOSE To assess the risk factors, incidence and significance of pneumothorax in patients undergoing CT-guided lung biopsy. METHODS Patients who underwent a CT-guided lung biopsy between August 10, 2010 and September 19, 2016 were retrospectively identified. Imaging was assessed for immediate and delayed pneumothorax. Records were reviewed for presence of risk factors and the frequency of complications requiring chest tube placement. 604 patients were identified. Patients who underwent chest wa...
#1Marcia A. Friedman (OHSU: Oregon Health & Science University)H-Index: 4
#2Brian Le (OHSU: Oregon Health & Science University)H-Index: 1
Last. James T. Rosenbaum (Legacy Health)H-Index: 87
view all 10 authors...
This is a prospective, open-label, proof-of-concept study of tofacitinib, a Janus kinase inhibitor, as a steroid-sparing therapy in corticosteroid-dependent pulmonary sarcoidosis. Five patients with corticosteroid-dependent pulmonary sarcoidosis were treated with tofacitinib 5 mg twice daily. The primary endpoint was a ≥ 50% reduction in corticosteroids at week 16 with no worsening in pulmonary function or respiratory symptoms. 60% of patients (3/5) met the primary endpoint. One patient was lost...
1 CitationsSource
Top fields of study
Diabetes mellitus